A clinical researcher with a multi-pipette arrangement of cancer stem cells. (Photo: Science Photo, via Shutterstock)One of the nation’s leading regenerative medicine industry groups is touting multi-billion dollar savings that may be achieved with the type of stem cell and gene therapies that are being developed with cash from California’s financially beleaguered stem cell program.
Stem cells for treating cancer in microtubes. (Image: Science Photo, via Shutterstock)Backers of the financially stressed California stem cell agency yesterday filed their proposed ballot measure to refinance the agency with $5.5 billion if voters approve it in November 2020. The complex, 30-page initiative would also restructure a number of aspects of the agency and provide for financial assistance for patients and their families who might be involved in clinical trials.
Stem cell research using what's known as a PCR strip. (Image: Science Photo via Shutterstock) Backers of a California ballot initiative to provide $5.5 billion more for the state’s cash-strapped stem cell agency say they will take their first official step by the end of this month.That’s when they will submit the proposed measure to California election officials and trigger a many-months-long process. The effort is aimed at ensuring that the nearly 15-year-old research effort survives in a meaningful way beyond next year.